Rapt Therapeutics Inc is a biopharmaceutical company that focuses on developing oral small molecule therapies for cancer and inflammatory diseases. The company was founded in 2015 and is based in South San Francisco, California, USA. Rapt Therapeutics is relatively young but has quickly gained prominence in the biotech industry due to its innovative approach to drug development.
The primary objective of Rapt Therapeutics is to develop targeted therapies that modulate the CCR4 receptor, a key component of the immune system. By targeting this receptor, Rapt aims to harness the body's immune response to combat cancer and inflammatory diseases more effectively. The company's drug candidates aim to restore the balance of immune cells in the tumor microenvironment, leading to potential benefits in cancer treatment.
One of Rapt Therapeutics' lead drug candidates is FLX475, which is under investigation for various types of cancer. FLX475 is designed to selectively target the CCR4 receptor on specific immune cells, potentially promoting an anti-tumor immune response. The company is conducting clinical trials to evaluate the safety and efficacy of FLX475 in cancer patients.
In addition to its focus on cancer, Rapt Therapeutics is also exploring the potential of its drug candidates in inflammatory and autoimmune diseases. Targeting the CCR4 receptor may have applications in modulating immune responses and reducing inflammation in various disease conditions.
Rapt Therapeutics collaborates with academic institutions, research organizations, and other biotechnology companies to enhance its drug discovery and development efforts. These collaborations provide the company with access to diverse expertise and resources, contributing to its scientific advancements in cancer and immunology research.